Leqembi market report sees faster growth across regions

The Business Research Company says the Leqembi market is expanding as Alzheimer’s cases rise, early diagnosis improves and demand grows for disease-modifying therapies. The report flags North America as the largest market in 2025 and Asia-Pacific as the fastest-growing region over the forecast period.

Why it matters: - Leqembi is part of a broader shift in Alzheimer’s care toward therapies that try to slow disease progression, not just manage symptoms. - Rising patient counts, broader diagnostic use and payer coverage could expand access to treatment and support market growth through 2035.

What happened: - The Business Research Company published its Leqembi Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report covers market size, growth factors, regional trends, key segments and leading competitors in the Leqembi market. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - Leqembi, also called lecanemab, is a prescription medicine developed to treat Alzheimer’s disease. - The drug targets amyloid-beta plaques in the brain, which are believed to contribute to the disease. - Leqembi is designed to slow memory loss, cognitive decline and daily functioning challenges linked to Alzheimer’s. - The report identifies rising Alzheimer’s prevalence as a major market driver. - The report points to more investment in neurodegenerative disease research, wider use of early diagnostic tools and personalized treatment protocols as growth factors. - The forecast also highlights stronger use of amyloid-targeting drugs, early-stage intervention, biomarker-guided patient selection and improved cognitive monitoring. - In September 2024, the European Brain Council reported that about 7 million Europeans were living with Alzheimer’s disease, with that number projected to reach 14 million by 2030. - In June 2024, Eisai Co., Ltd. and Biogen Inc. said the U.S. Food and Drug Administration accepted a supplemental biologics license application for a monthly intravenous maintenance dosing regimen of Leqembi. - The maintenance dosing plan is intended to reduce treatment frequency while continuing to target toxic amyloid protofibrils linked to cognitive decline. - The report also includes Western Europe, Eastern Europe, South America, the Middle East and Africa in its regional analysis. - The 2026 report package includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated graphics and tables. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The report frames Leqembi as a beneficiary of a larger industry move toward earlier intervention and biomarker-based treatment selection. - The FDA filing for monthly maintenance dosing suggests manufacturers are trying to make long-term treatment easier to deliver and more attractive to patients and providers. - North America’s lead likely reflects stronger healthcare infrastructure and earlier adoption, while Asia-Pacific’s growth points to rising awareness and spending in newer markets.

What's next: - The market’s trajectory will depend on how quickly early diagnosis spreads, how widely payers cover therapy and how strongly clinicians adopt disease-modifying Alzheimer’s drugs. - Eisai and Biogen’s monthly dosing application could further shape treatment uptake if regulators move it forward. - The report’s forecast period runs through 2035, leaving room for additional regional adoption and product updates.